TOP-003 | Model for end-stage liver disease score-based liver allocation is associated with reduced survival in low donation countries a comparative analysis between Germany and the USA | Leke Wiering | Received |
TOP-012 | Validation of transient elastography and the enhanced liver fibrosis test as prognostic biomarkers across the spectrum of steatotic liver disease | Nikolaj Torp | Received |
WED-027 | Long-term post-transplant emergence of metabolic syndrome is associated with gut microbial metabolites in urinary metabolomics | Jane Cox | Received |
SAT-028 | The relationship between spleen stiffness and portal hypertension liver transplant patients | Kanan Nuriyev | Received |
SAT-030 | A visual classification scale of biliary anastomotic strictures with per-oral cholangioscopy predicts outcomes in liver transplant recipients | Andres Cardenas | Received |
SAT-036 | Impact of distance from liver transplant centre on outcomes following liver transplantation - an australian single centre study | Simone Chin | Received |
FRI-038 | Silver-coating of tunneled peritoneal drainage system is associated with a lower incidence of peritonitis and device explantation | Sarah Lisa Schütte | Received |
FRI-039 | Terlipressin therapy is associated with increased risk of colonization with multidrug-resistant bacteria in patients with decompensated cirrhosis | MARCUS MÜCKE | Received |
SAT-040 | Is there a need to screen for ischemic heart disease in liver transplant candidates without coronary calcification on routine chest CT? | Susan Fischer | Received |
FRI-041 | Evaluating the influence of human albumin infusions on the MELD and MELD-Na scores in patients hospitalized with an acute decompensation of cirrhosis: an ATTIRE trial analysis | Nikolaj Torp | Received |
FRI-042 | Comparison of clinical outcomes among patients with refractory ascites and implantation of either Alfapump, tunneled peritoneal drainage system or transjugular intrahepatic portosystemic shunt | Sarah Lisa Schütte | Received |
WED-055 | Effect of long-term treatment with Simvastatin and Rifaximin in mitochondrial and proinflammatory pathways in patients with decompensated cirrhosis. A single-cell RNA seq analysis in PBMCs | Adriŕ Juanola | Received |
WED-056 | Activated cytotoxic T-cells in mesenteric lymph nodes limit systemic bacterial dissemination, inflammation, and disease progression in chronic liver injury | Pinky Juneja | Received |
WED-058 | High shear stress induced PIEZO1 activation promotes cytoskeleton remodelling and a nuclear deformation develops pro-thrombotic microenvironment and contributes to portal hypertension | Rajni Yadav | Received |
FRI-059 | Proton pump inhibitors are not associated with an increased risk of hepatic encephalopathy | Simon Johannes Gairing | Received |
WED-060 | Type-I interferon shapes peritoneal immunity in cirrhosis, driving caspase-5-mediated progranulin release during spontaneous bacterial peritonitis | Michael Rooney | Received |
TOP-061 | Whole blood thrombin generation improves the understanding of cirrhotic coagulopathy and predicts clinical outcomes in patients with cirrhosis: a prospective cohort study | Alberto Zanetto | Received |
TOP-064 | Impact of bacterial infections on kidney function and survival in patients with decompensated cirrhosis and acute kidney injury worldwide analysis of the ICA-GLOBAL AKI study | Adriŕ Juanola | Received |
TOP-065 | Outcomes of thromboelastography guided versus routine empirical or on-demand platelet transfusion in patients with liver cirrhosis and severe thrombocytopenia undergoing high-risk invasive percutaneous and vascular procedures: an open-label, randomized controlled trial | Sagnik Biswas | Received |
TOP-066 | Development and validation of a prognostic model (AMMON-AD) to define risk of overt hepatic encephalopathy in cirrhosis patients with acute decompensation | María Pilar Ballester | Received |
SAT-068 | Accuracy of spleen stiffness measurement for the diagnosis of high-risk esophageal varices in patients with advanced chronic liver disease: a systematic review and individual patient data meta-analysis | Elton Dajti | Received |
WED-068 | Cell-free DNA dynamics in advanced cirrhosis: unravelling the role of nuclear and mitochondrial DNA in inflammation, coagulation dysfunction and short-term mortality | Marilena Stamouli | Received |
WED-069 | Bone morphogenic protein 9 (BMP9): a novel therapeutic agent for the prevention of extrahepatic organ failure in acute-on-chronic liver failure (ACLF) | Alexandra Phillips | Received |
WED-070 | Isolation and immortalization of human endothelial cells from the portal vein | Aina Anton | Received |
TOP-072 | Red blood cell distribution width-to-platelet ratio estimates the 3-year risk of decompensation in patients with metabolic dysfunction-associated steatotic liver disease-related cirrhosis | Mario Romeo | Received |
FRI-093 | Clot wave analysis parameters are associated with the severity of liver cirrhosis | Kessarin Thanapirom | Received |
TOP-096 | Glucagon-like peptide-1 receptor agonist, semaglutide attenuates liver cirrhosis-related skeletal muscle atrophy in diabetic mice | Kosuke Kaji | Received |
THU-100 | Factors associated with the real-world biochemical response to fibrate therapy in primary biliary cholangitis | Maria van Hooff | Received |
THU-101 | Non-invasive assessment of portal hypertension in patients with primary biliary cholangitis is affected by severity of cholestasis | Ciro Celsa | Received |
THU-102 | Specific glycomic profiles can identify patients at risk of poor transplant-free survival in primary biliary cholangitis | Nicky Somers | Received |
SAT-105 | Neutrophil extracellular traps are not linked to the development of decompensation, ACLF, or death in clinically stable patients with advanced chronic liver disease | Lorenz Balcar | Received |
SAT-106 | Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) predicts acute-on-chronic liver failure in patients with acute decompensation | Lorenz Balcar | Received |
THU-106 | Prospective european reference network registry (R-LIVER) supports improvement in bone disease care delivery at local level for patients with autoimmune liver diseases and enables detailed description of risk elements | Boglarka Bozso | Received |
THU-109 | Increasing prevalence of primary biliary cholangitis in The Netherlands | Rozanne de Veer | Received |
SAT-113 | Long-term therapy with intravenous human albumin increase survival in patients with decompensated cirrhosis and refractory ascites | Antonino Lombardo | Received |
SAT-117 | Evaluation of Baveno VII criteria and other non-invasive tests for clinically significant portal hypertension in chronic hepatitis D | Mathias Jachs | Received |
FRI-118 | Independent association of loss of skeletal muscle mass with long-term liver-related mortality in cirrhotic patients | Jiarui Zheng | Received |
FRI-127 | The relationship between abnormal body composition by computed tomography imaging and long-term mortality in patients with cirrhosis | Rui Huang | Received |
SAT-129 | Role of serum Mac-2 binding protein glycosylation isomer in identifying patients with chronic liver diseases at risk for portal hypertension-related complications | Kessarin Thanapirom | Received |
WED-131 | Von Willebrand factor antigen reflects portal hypertension severity in porto-sinusoidal vascular disorder and predicts liver-related outcomes | Lorenz Balcar | Received |
FRI-131 | Effect of adipose-related parameters on survival in patients with cirrhosis: a systematic review and meta-analysis | Xinxing Tantai | Received |
FRI-132 | Spontaneous bacterial empyema is a rare yet life-threatening complication in patients with hepatic hydrothorax | Grace Wong | Received |
WED-135 | Impact of metabolic alterations on liver phenotype of patients with homozygous alpha-1 antitrypsin deficiency (Pi*ZZ) | Christina Schrader | Received |
TOP-141 | Longitudinal assessment of individuals with homozygous alpha-1 antitrypsin deficiency (Pi*ZZ genotype) provides evidence for clinical patient management | Malin Fromme | Received |
TOP-142 | Safety and efficacy of direct oral anticoagulants in cirrhotic and non-cirrhotic splanchnic vein thrombosis | Lucia Giuli | Received |
TOP-143 | Porto-sinusoidal vascular disease among patients undergoing surgery for liver metastases: prevalence, non-invasive diagnosis, and burden on surgical outcomes | Elton Dajti | Received |
TOP-144 | Heterozygosity for rare Apolipoprotein B variants predispose to severe metabolic associated steatotic liver disease | Matteo Mureddu | Received |
TOP-148 | Interleukin-2 mediated regulatory T cell expansion is associated with dual outcomes of ductular reaction and liver fibrosis | Man Chun Wong | Received |
TOP-149 | Plasmatic expression of miR122-5p and miR21-5p predicts relapse of autoimmune hepatitis after treatment withdrawal | Pinelopi Arvaniti | Received |
TOP-150 | Molecular analysis of checkpoint inhibitor-induced liver injury | Sarp Uzun | Received |
SAT-151 | The role of interleukin-8 in primary sclerosing cholangitis-associated immune cell dysregulation | Lander Heyerick | Received |
FRI-152 | Gene editing to treat liver metabolic disorders: harnessing paired Cas9-Nickases for efficient and safe treatment of primary hyperoxaluria type 1 | Laura Torella | Received |
SAT-153 | Single-cell RNA sequencing identifies the fundamental role of intrahepatic CD8 T cells in the pathogenesis of autoimmune hepatitis | Ignasi Olivas | Received |
SAT-154 | Studying cholangiocyte properties and functions using a bile duct on a chip | Henry Hoyle | Received |
SAT-155 | Impaired hepatic sympathetic neuronal communication intensifies hepatic inflammation, fibrosis and metabolic dysregulation, exacerbating liver injury | sadam BHat | Received |
WED-171 | Spleen stiffness and VWF-based non-invasive tests reflect severity of prehepatic and presinusoidal portal hypertension | Lorenz Balcar | Received |
SAT-176 | Itg-Cre/DTA mice develop the autoimmune biliary disease that serologically and pathogenically models human primary biliary cholangitis | Jiaqi Zhang | Received |
WED-190 | Elevated hepatic copper content in porto-sinusoidal-vascular disorder: leading down a wrong track | Lorenz Balcar | Received |
FRI-194 | Risk of all-cause mortality and adverse outcomes from steatotic liver disease and its subgroups in the general population | Maurice Michel | Received |
WED-198 | Novel deep learning models utilising domain adaptation outperform conventional statistical models for predicting the risk of liver-related complications in patients with metabolic dysfunction-associated steatotic liver disease | Terry Cheuk-Fung Yip | Received |
TOP-228 | CD36-mediated hepatocyte-macrophage coordination drives hepatic fibrosis in NAFLD | Zhe Dai | Received |
TOP-229 | The E2F2 target glycerophosphodiester phosphodiesterase domain containing 3 is involved in MASLD progression to HCC and related dyslipidemias | Maider Apodaka Biguri | Received |
WED-231 | Machine learning-based mortality prediction models for non-alcoholic fatty liver disease in the general United States population | Jiarui Zheng | Received |
FRI-234 | Association between the duration of comorbidities and steatotic liver disease | HA IL KIM | Received |
SAT-237 | Efficacy and safety of FGF21 analogues in the treatment of metabolic dysfunction-associated steatohepatitis: an updated systematic review and meta-analysis | Gilmara Coelho Meine | Received |
TOP-241 | Longitudinal changes in liver stiffness measurements in a population-based screening cohort of 5,517 participants | Katrine Bech | Received |
SAT-244 | FGF-19 analogues for the treatment of metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis | Gilmara Coelho Meine | Received |
THU-249 | The role of the ferroptosis brake glutathione peroxidase 4 in a preclinical model of metabolic dysfunction-associated steatohepatitis | Wilhelmus Kwanten | Received |
WED-249 | Improved risk stratification by combination of FIB-4 with FGF21 serum levels in steatotic liver disease | Heike Bantel | Received |
TOP-252 | Longitudinal changes in FIB-4 do not predict outcomes in patients with metabolic dysfunction-associated steatotic liver disease | Hannes Hegmar | Received |
WED-257 | FibroScan compared to liver biopsy for accurately detecting recurrent hepatic steatosis and fibrosis after liver transplantation for metabolic dysfunction-associated steatohepatitis | Laura Martínez-Arenas | Received |
SAT-260 | Metadoxine improves alcohol abstinence and is related to a lower risk of decompensation in cirrhosis at a median five-year follow-up: propensity score matching analysis | Fatima Higuera | Received |
WED-266 | Age impacts the diagnostic ability of the enhanced liver fibrosis test for advanced fibrosis in MASLD | Katrina Pekarska | Received |
TOP-276 | Time-trends of fibrosis and steatosis in metabolic dysfunction-associated steatotic liver disease (MASLD): a retrospective cohort analysis | Umang Arora | Received |
TOP-277 | Liver fibrosis assessed via non-invasive tests is associated with incident heart failure in a general population cohort: a UK Biobank study | Theresa Hydes | Received |
FRI-298 | Insulin resistance and sarcopenia as comorbid conditions in patients with MASLD | Kateryna Pivtorak | Received |
SAT-302 | Long-term trends in the prevalence of alcohol-related cirrhosis among national U.S. veterans affairs data and territory wide Hong Kong data an east-west perspective | Robert Wong | Received |
TOP-311 | Subtypes of steatotic liver disease have differing clinical outcomes | Katrina Pekarska | Received |
FRI-318 | NGFR inhibition by TAT-Pep5 protects mice from acetaminophen-induced liver injury | Laura Kitto | Received |
WED-318 | Steatotic liver disease in diabetic patients: more serious diabetes mellitus, more serious liver disease | Zülal &304;stemihan | Received |
WED-320 | Optimizing non-alcoholic fatty liver disease care using mac-2 binding protein glycosylation isomer and correlations with advanced diagnostics | Minh Khue Nguyen | Received |
FRI-324 | Advancing in drug-induced liver injury models development: high content screening in cell-based models derived from skin tissues | Antonio Segovia-Zafra | Received |
TOP-329 | Integrated plasma multi-omics analysis classifies key mycobiome, microbiome and metabolome changes linked to development of poor outcome in severe alcoholic hepatitis | GAURAV TRIPATHI | Received |
SAT-338 | Using retrieval augmented generation to increase large language models accuracy: a proof-of-concept pipeline on european hepatitis C virus (HCV) guidelines | Mauro Giuffre | Received |
TOP-344 | Identifying spontaneous recovery in acute liver failure; a machine learning model | Xun Zhao | Received |
TOP-346 | Therapeutic plasma exchange in Amatoxin associated acute liver failure results from an interim analysis of the Amanita-PEX study | Dr. Bahar Nalbant | Received |
FRI-348 | Endogenous Annexin A1 has a protective effect on the liver in a diabetic mouse model | Diego Dias dos Santos | Received |
TOP-349 | Plasma lipidomics and fungal peptide-based community analysis identifies signatures of severity and early mortality in acute liver failure | Neha Sharma | Received |
TOP-350 | Differential DNA methylation as a potential drug-induced liver injury biomarker and genome-wide DNA methylation functional analysis | Marina Villanueva | Received |
TOP-351 | A dual therapeutic strategy for acute liver failure: SIRP&945;-expressing extracellular vesicles from engineered mesenchymal stem cells for resolving CD47 in necroptotic hepatocytes and delivering regenerative cargo | Seohyun Kim | Received |
TOP-352 | Serum proteomics can help identify new prognostic biomarkers in adults with acute liver failure | Katharina Remih | Received |
TOP-355 | T cells expressing HBV-specific chimeric antigen receptors harboring a Fab fragment control HBV infection in mice | Zhe Xie | Received |
TOP-358 | Non-HAP CAM-A ALG-006746 and ALG-006780 induce rapid HBsAg reductions in AAV-HBV mice and have favorable pharmacokinetic profiles | Yannick Debing | Received |
TOP-359 | Development of a replication-competent Vesicular Stomatitis Virus (VSV) vector for therapeutic hepatitis B vaccination | Jinpeng Su | Received |
FRI-361 | Burden of liver disease progression in patients with chronic HDV infection: a population-based study for France | Lucia Parlati | Received |
FRI-362 | Hepatitis B surface antigen (HBsAg) seroclearance following discontinuation of nucleos(t)ide analogues (NA) treatment has comparable durability to HBsAg seroclearance achieved during NA therapy | Terry Cheuk-Fung Yip | Received |
FRI-363 | Association between metabolic comorbidities, severity of liver fibrosis and fibrosis regression in patients with chronic hepatitis B an individual patient data meta-analysis | Lisa van Velsen | Received |
SAT-365 | Hepatitis B virus mutations associated with hepatocellular carcinomas are regulated by HLA genotype | Masaya Sugiyama | Received |
FRI-367 | Prediction of hepatocellular carcinoma risk and liver-related events in chronic hepatitis D, an international retrospective cohort study (RIDE) | Lesley Patmore | Received |
TOP-369 | HEV replication and genomic diversification in the human kidney | André Gömer | Received |
FRI-373 | Impact of pregnancy on global and HBV-specific B-cell immunity | Anna Pocurull | Received |
THU-378 | Prediction of outcomes in patients with HCV compensated liver cirrhosis after SVR: results from 5-years of follow-up | Luisa Ranieri | Received |
SAT-379 | Immune checkpoint proteins are associated with persistently elevated liver stiffness after successful HCV therapy in people with HIV | Rubén Martín Escolano | Received |
TOP-384 | Macrophage-augmented organoids recapitulate the complex pathophysiology of viral diseases affecting the liver and devise advanced treatment strategies | Kuan Liu | Received |
TOP-385 | Evaluation of liver fibrosis in patients with advanced chronic liver disease due to hcv after 6 years of sustained viral response. study with paired biopsies at 3 and 6 years | Lidia Canillas Alavés | Received |
FRI-389 | Hepatitis delta virus infection is associated with significantly greater incidence of cirrhosis and hepatic decompensation in U.S. veterans with chronic hepatitis B | Robert Wong | Received |
TOP-401 | Improvement of liver stiffness during nucleo(s)tide analogue treatment in patients with chronic hepatitis B and advanced fibrosis is not associated with a reduction in hepatocellular carcinoma risk | Lesley Patmore | Received |
WED-402 | Risk of hepatocellular carcinoma after curative treatment when switching from Tenofovir Disoproxil Fumarate or Entecavir to Tenofovir Alafenamide: a real-world multicenter cohort study | Hyunjae Shin | Received |
SAT-407 | Long-term sustained decline of anti-HCV neutralizing antibodies in HIV/HCV-coinfected patients after therapy-induced HCV clearance | Daniel Sepúlveda-Crespo | Received |
THU-407 | A new pattern for hepatitis C management in hospital: establishment and effectiveness verification | Siheng Zhu | Received |
WED-413 | 10-year results under tenofovir disoproxil fumarate and entecavir in chronic hepatitis B; HBV clearance rare, disease outcomes good | Zülal &304;stemihan | Received |
WED-420 | Evaluation of molnupiravir as an antiviral against hepatitis E virus infection | Siddharth Sridhar | Received |
SAT-425 | Food swamps and easy access to unhealthy food increases the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) mortality in the United States (U.S.) | Carey Escheik | Received |
SAT-426 | Prevalence and association between chronic kidney disease and steatotic liver disease in a nationally representative sample in the United States | Mason Lai | Received |
SAT-427 | Hepatocellular carcinoma surveillance in the United Kingdom: a multi-centre study assessing uptake and inequalities | Maria Qurashi | Received |
WED-428 | Patient, provider, and neighborhood-level factors associated with hepatitis delta testing in an academic health system | Lauren Alpert | Received |
WED-429 | Hepatitis B virus care cascade in Rwanda: a population based-study | Jean Damascene Makuza | Received |
WED-438 | Real-world based cost effectiveness analysis of entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy | CHUN-TING HO | Received |
WED-440 | Community-based interventions to increase hepatitis B virus and hepatitic C virus infections screening among at-risk migrant and refugee populations in Italy, Greece, and Spain: 1-year results of the VH-COMSAVAC project | CAMILA A PICCHIO | Received |
WED-441 | Precise estimation of national HBV prevalence: the importance of double hepatitis B surface antigen and hepatitis B core antibody testing in low endemic countries | Arno Furquim dAlmeida | Received |
WED-442 | Decreasing trend of hepatitis C in homeless people between 2019-2023: a retrospective study in Madrid, Spain | Daniel Sepúlveda-Crespo | Received |
TOP-445 | Associations of food insecurity and healthcare access with the prevalence and mortality of metabolic dysfunction-associated steatotic liver disease (MASLD): a global study of the United Nation and the global burden of disease data | Carey Escheik | Received |
FRI-456 | Characterization of the intratumoral immune microenvironment of hepatocellular carcinoma before ive intrahepatic radiation therapy (SIRT) and study of its prognostic value on response to treatment | Maria Stella Franzč | Received |
THU-458 | No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC | Francisca Copil | Received |
FRI-459 | Outcome of targeting ATR in high replication stress murine HCC | JING FANG | Received |
THU-459 | Long-term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma: a multicentric retrospective study | Clémentine ALITTI | Received |
TOP-460 | Progression of hepatitis B virus (HBV)-related liver disease in immune-tolerant, inactive, and grey zone phases: a systematic review & meta-analysis | Zakary Warsop | Received |
TOP-461 | Retreating the off-Nuc clinical relapse with Pegylated interferon much increased HBsAg seroclearance a propensity score matching study | Yu-Ting Kao | Received |
FRI-462 | Aminoacyl-tRNA synthetases characterization and clinical potential in aggressive hepatocellular carcinoma | Natalia Hermán-Sánchez | Received |
FRI-463 | Identifying unique cell states in early liver oncogenesis with transcription coupled repair | Elizabeth Carmichael | Received |
FRI-464 | Caspases compromise SLU7 and UPF1 stability and nonsense-mediated RNA decay activity during hepatocarcinogenesis | Carmen Berasain | Received |
FRI-466 | Implications and therapeutic potential of neddylation for pediatric liver cancer: hepatoblastoma | Leidy Estefanía Zapata-Pavas | Received |
THU-466 | Treatment with Atezolizumab-Bevacizumab for hepatocellular carcinoma in the french population outside clinical trials: data from the prospective CHIEF cohort | Manon Allaire | Received |
FRI-467 | Efficacy of WNTinib, a novel ive therapeutic for CTNNB1 mutant tumors, in preclinical models of hepatoblastoma | Ugne Balaseviciute | Received |
FRI-470 | Deciphering the role of FXR in the rewiring of Treg polarization in hepatocellular carcinoma | Yasmeen Attia | Received |
SAT-474 | Lesions hyper- to isointense to the surrounding liver in the hepatobiliary phase of gadoxetic acid enhanced MRI | Alicia Furumaya | Received |
SAT-477 | The impact of etiology on patterns of progression of advanced HCC | Bernardo Stefanini | Received |
SAT-484 | Conventional and machine-learning based risk score on survival for patients with hepatocellular carcinoma | CHUN-TING HO | Received |
TOP-488 | Fecal microbiota transplant combined with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab interim analysis of the FAB-HCC phase II pilot study | Katharina Pomej | Received |
TOP-489 | Predicting post-hepatectomy liver failure in patient with hepatocellular carcinoma: nomograms based on deep learning-analyzed gadoxetic acid-enhanced hepatobiliary phase images | Boryeong Jeong | Received |
SAT-497 | A risk prediction model for hepatocellular carcinoma in general population without traditional risk factors for liver disease | Byeong Geun Song | Received |
TOP-507 | Single-cell RNA sequencing-derived gene signatures reveal distinct response mechanisms to atezolizumab bevacizumab in advanced hepatocellular carcinoma | Sarah Cappuyns | Received |
TOP-509 | Validation and improvement of the IMbrave050 criteria for high-risk of HCC-recurrence as an indication to adjuvant treatment: results from a 4-year retrospective competitive-risk study | Federico Ravaioli | Received |
TOP-511 | Trends and evolution of hepatocellular carcinoma due to etiological shift from 2005 to 2020 in Germany: nationwide population-based study | Josune Cabello Calleja | Received |
SAT-515 | Cholangiocarcinoma across England: evidence of regional, socioeconomic, and temporal variations in incidence, survival, routes to diagnosis and treatment | Shahid Khan | Received |
WED-518 | Protein-modulated microbiota for fecal transplantation improves metabolic functions in alcohol-related liver disease model | Nishu . | Received |
TOP-520 | Machine learning for risk stratification of hepatocellular carcinoma | Jan Clusmann | Received |
SAT-531 | Testosterone modulates T cells in healthy individuals and women with autoimmune liver disease | Nico Will | Received |
SAT-532 | Distinct soluble and cellular immunological signatures in various entities of hepatitis flares | Roni Souleiman | Received |
SAT-534 | Macrophage-derived IL-15 imprints peritoneal tissue-resident memory T cells during spontaneous bacterial peritonitis in patients with cirrhosis | Oluwatomi Ibidapo-obe | Received |
SAT-535 | The role of the immune checkpoint TIGIT in CD4 T cell dysfunction in patients with decompensated cirrhosis | Joseph Delo | Received |
FRI-547 | Regenerative matrix-based hydrogels repair hepatocellular damage and promote cellular proliferation in pre-clinical models of acute liver injury | Ashwini Vasudevan | Received |
THU-549 | Pioglitazone ameliorates fibrotic niche of HBV transgenic mice by restoring NK cell function and inhibiting macrophage activation | Huanyu Xiang | Received |
TOP-552 | Oncogenic beta-catenin uses CD155 as a molecular actor to corrupt immunosurveillance of cold HCC | Joana Gonalves Araujo | Received |
FRI-555 | New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: a human and experimental study | Matias A Avila | Received |
TOP-561 | Butyrate induces epigenetic and metabolic reprogramming in myeloid-derived suppressor cells to alleviate primary biliary cholangitis | Rui Wang | Received |
5-8 June, Milan
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|